| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | PD173074 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | 0.067 | 0.04 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.05 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.05 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.12 | 0.05 |